» Articles » PMID: 1550111

Increased Expression of Natural-killer-associated and Activation Antigens in Multiple Myeloma

Overview
Journal Am J Hematol
Specialty Hematology
Date 1992 Feb 1
PMID 1550111
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The expression of both natural-killer (NK)-associated and activation antigens was studied by flow cytometry in the peripheral blood of 47 untreated multiple myeloma (MM) patients. A significant increase in both absolute and relative numbers of CD57 positive cells as well as in the proportion of CD16 and CD11b cells was observed in patients with MM, specially in those in early stages of the disease (clinical stages I and II), suggesting a possible surveillance mechanism in response to an emerging malignant clone. Additional double stainings showed that strong CD16+ NK cells coexpress the CD56, CD11b, and CD2 antigens, while they lacked CD3, CD5, and WT31 antigens. Moreover, the previously reported increase in CD8 cells present in MM would be mainly due to a subset of CD8 cells that coexpress the CD57 Ags. The expression of activation antigens, especially CD38, was increased in peripheral blood lymphocytes of MM patients, the differences reaching statistical significance both in absolute and relative numbers in those cases with high numbers of CD16 NK cells and thus suggesting that these cells are functionally activated. These results reveal the existence of an increase in NK and activated cells in the peripheral blood of myeloma patients that may reflect a host's immunological mechanism in an attempt to modulate tumor cell growth.

Citing Articles

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L Front Immunol. 2017; 8:1444.

PMID: 29163516 PMC: 5682004. DOI: 10.3389/fimmu.2017.01444.


Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.

Lee S, Lim J, Ryu D, Kim T, Yoon J, Cho B Cancer Immunol Immunother. 2016; 65(8):983-94.

PMID: 27342591 PMC: 11029332. DOI: 10.1007/s00262-016-1861-2.


A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson Jr D, Cohen A, Jagannath S, Munshi N, Spitzer G, Hofmeister C Clin Cancer Res. 2015; 21(18):4055-61.

PMID: 25999435 PMC: 4573800. DOI: 10.1158/1078-0432.CCR-15-0304.


The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Dosani T, Carlsten M, Maric I, Landgren O Blood Cancer J. 2015; 5:e306.

PMID: 25885426 PMC: 4450330. DOI: 10.1038/bcj.2015.32.


Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Tete S, Bijl M, Sahota S, Bos N Front Immunol. 2014; 5:257.

PMID: 24917865 PMC: 4042361. DOI: 10.3389/fimmu.2014.00257.